### TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Activity</th>
<th>Number of respondents</th>
<th>Number of responses per respondent</th>
<th>Total annual responses</th>
<th>Average burden per response</th>
<th>Total hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort 2—Youth Aged 11 to 18.</td>
<td>Cohort 2—Youth Baseline Questionnaire, Cohort 2—Youth 1st, 2nd, 3rd Followup Questionnaire.</td>
<td>2,667</td>
<td>1</td>
<td>2,667</td>
<td>0.75 (45 minutes)</td>
<td>2,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6,270</td>
<td>1</td>
<td>6,270</td>
<td>0.75 (45 minutes)</td>
<td>4,703</td>
</tr>
<tr>
<td>Totals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16,525</td>
</tr>
</tbody>
</table>

*There are no capital costs or operating and maintenance costs associated with this collection of information.*

To accommodate the additional data collection for media tracking, FDA requests approval to increase the number of burden hours under the existing control number. The previous number of approved screener responses for media tracking was 60,000 and the associated burden was 1,800 hours. The previous burden for the media tracking questionnaires was 6,000 and the associated burden was 3,000 hours. We are requesting an additional 20,000 screener responses and 2,000 questionnaire completions, which adds 600 burden hours and 1,000 burden hours respectively. Deducting the responses and burden for the completed evaluation components associated with Cohort 1 (general population screening (13,413 responses, 2,281 hours), parent interviews (3,342 responses, 569 hours), youth questionnaires (8,954 responses, 6,144 hours)) and for the rural smokeless evaluation (2,610 responses, 569 hours)) and for the rural smokeless evaluation (2,610 responses, 569 hours) results in a decrease of 6,319 annual responses and 9,187 hours.

Dated: May 14, 2019.
Lowell J. Schiller, Principal Associate Commissioner for Policy.

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

**National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; Resources for Technology Dissemination (U24) Review Meeting (2019/08).
**Date:** June 27, 2019.
**Time:** 9:00 a.m. to 7:30 p.m.
**Agenda:** To review and evaluate grant applications.
**Place:** National Institutes of Health, Two Democracy Plaza, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
**Contact Person:** Dennis Hlasta, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Two Democracy Boulevard, Suite 920, 6707 Democracy Blvd., Bethesda, MD 20892, 301–451–4794, dennis.hlasta@nih.gov.

Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–10235 Filed 5–16–19; 8:45 am]
BILLING CODE 4140–01–P

---

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

**National Institutes of Health**

**National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Alcohol Abuse and Alcoholism.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Advisory Council on Alcohol Abuse and Alcoholism.
**Date:** June 6, 2019.
**Time:** 1:30 p.m. to 2:15 p.m.
**Agenda:** To review and evaluate grant applications.
**Place:** National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Room 1206, Bethesda, MD 20892 (Telephone Conference Call).
**Contact Person:** Abraham P. Bautista, Ph.D., Executive Secretary, National Advisory Council, Director, Office of Extramural Activities, National Institute On Alcohol Abuse And Alcoholism, 6700 B...